European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice…

By G. D. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cífková, J. Dallongeville, Shah Ebrahim, O. Faergeman, I. Graham, G. Mancia and 11 more. Archives des maladies du coeur et des vaisseaux, 2004

631 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/dc3c522451d1523c795925d8aaeb70f90836779f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Hiatt
2. L. Norgren
3. M. Nehler
4. K. Harris
5. F. Fowkes
6. J. Dormandy
7. M. Conte

Citations in the corpus

• Family Health Behaviors (2017, unknown): “Our prediction relies on risk factors used by medical practitioners (De Backer et al. 2003; Pencina et al. 2014), constrained to those observable in our data.”
• EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries (2016, unknown): “2015–1:13pm] [1–13] //blrnas3.”
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, unknown): “In the 2003 guidelines [44], a 10-year risk of CVD death of ≥5 % was arbitrarily considered high risk.”
• Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). (2007, background): “59 mmol/L ( 100 mg/dL) and to treat the increased triglyceride and low HDL pattern.(41,42) The recent ACC/ AHA guidelines recommend as a general treatment goal achieving an LDL cholesterol level 2.”